Astellas Pharma

GPTKB entity

Statements (45)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:acquisition gptkb:OSI_Pharmaceuticals
gptkb:Iveric_Bio
gptkbp:awards gptkb:Top_Employer_Japan
Diversity_&_Inclusion_Award
Best_Workplaces_in_Japan
gptkbp:CEO gptkb:Kenji_Yasukawa
gptkbp:clinicalTrials invests heavily in clinical research
conducts numerous clinical trials worldwide
gptkbp:collaborations with academic institutions
with healthcare organizations
with research institutes
gptkbp:employeeCount around 17,000
gptkbp:focus_area neurology
rare diseases
dermatology
cardiovascular diseases
infectious diseases
pain management
transplantation
gptkbp:founded 2005
gptkbp:global_presence operates in over 70 countries
gptkbp:headquarters gptkb:Tokyo,_Japan
https://www.w3.org/2000/01/rdf-schema#label Astellas Pharma
gptkbp:industry pharmaceuticals
gptkbp:market strong_presence_in_Europe
strong_presence_in_Asia
strong_presence_in_North_America
gptkbp:partnerships various biotech companies
gptkbp:patentCitation holds numerous patents in pharmaceuticals
gptkbp:philanthropy supports various health initiatives
contributes to community health programs
engages in educational initiatives
gptkbp:products oncology drugs
immunosuppressants
urology drugs
gptkbp:researchAndDevelopment focus on innovative medicines
gptkbp:revenue $12.5 billion (2022)
gptkbp:stockExchange 4503 (TSE)
gptkbp:subsidiary gptkb:Astellas_US_LLC
gptkb:Astellas_Pharma_Europe_Ltd.
gptkb:Astellas_Pharma_Canada_Inc.
gptkbp:sustainability_initiatives social responsibility
environmental responsibility
governance practices